The global large & small-scale bioprocessing (biopharmaceutical manufacturing) market size was estimated at USD 26.12 billion in 2016. Bioprocess engineering has been effectively explored for the development of biopharmaceuticals and it has provided bio manufacturers and contract manufacturing organizations (CMO) with lucrative avenues of growth. This, in turn, is expected to attract focused efforts to bolster the market adoption of various bioprocess engineering solutions.
Biopharmaceuticals manufacturing is expected to serve as the lucrative source of revenue within the pharmaceutical industry in the coming years. Hence, with the gradual shift of the pharmaceutical industry towards biopharmaceuticals, the bioprocessing market is also expected to grow at a significant pace throughout the forecast period.
Rapid advancements in bioprocess engineering, including the evolution of contract services and single-use technology, have contributed huge success to the biopharmaceutical manufacturing industry. Emerging innovations, such as nano-biocatalysts, aimed to improve the turnaround times by enhancing enzyme activity and stability to enhance the bioproduction, thus driving revenue generation.
Previously, only a handful of firms were able to handle the entire value chain of large-molecule bioproduction. However, in the current scenario, there are many companies in the space that are involved in the development of biologics and biosimilars owing to the technological advances in bioprocessing technology.
Driven by high demand for biopharmaceuticals, suppliers' product portfolio for biomanufacturing has become more robust. Suppliers of bioreactors and other ancillary bioprocessing equipment are undertaking endeavors to fulfill growing expectations of bio manufacturers concerning cost, space requirement, and portability.
Budgets for biomanufacturing operations are expanding in essentially all aspects. Companies are observed making significant investments in biomanufacturing-related R&D. This also includes hiring expert professionals and expansion of manufacturing capacity. These factors are expected to play a pivotal role in reshaping the bioprocessing of various products shortly.
Moreover, the introduction of high throughput process development and data analysis services enables entities to gain insight into the production process for product development and consequently optimizes the whole process. The evolution of bioremediation as a promising solution for cost-effective treatment of contaminants like heavy metals has also contributed to the enhanced adoption of bioprocessing equipment.
However, even though this market is expected to witness significant growth in the coming years, purification and stability issues regarding protein production as well as environmental concerns about the use of single-use bioprocessing equipment are expected to hamper the growth of the market to a certain extent.
The bioprocessing workflow comprises three stages viz., upstream processing, fermentation, and downstream processing based on activities carried out for conversion of crude raw material to final finished product.
Product purification which is the key step in downstream processing is considered as the most challenging & crucial step and thus, demands more attention. This factor has contributed to the large share of this segment in 2016.
Moreover, any advancement in bioprocessing engineering directly affects the production yield, which in turn, positions the downstream processing segment as the center of significant attraction of several major big pharma stakeholders.
However, with the advent of single-use technology coupled with growth in mammalian titer for production, upstream processing is expected to grow at a lucrative pace throughout the forecast period. Also, technological modifications in bioreactors and fermenters are projected to accelerate revenue growth for the fermentation segment in the coming years.
Bioreactors accounted for a substantial share of the revenue inflow owing to the high usage rate coupled with large-scale bioproduction requirements from key industry participants. Automated cell culturing using specialized bioreactor designs holds great significance for the development of value-added products, thereby influencing growth in this segment.
The availability of a wide range of bioreactors based on the operation mode, phase-type, capacity, fluid flow type, use type, and applications is expected to boost revenue generation in this segment soon. Other products offered in this market include bags & containers, filtration assemblies, cell culture products, and bioreactors accessories.
Cell culture product is the fastest-growing segment. This is mainly attributed to the ongoing advancements in cell line development including the development of the recombinant cell line. Production of biopharmaceutical derived cell lines from mammalian cell lines is supportive of the projected growth of this segment.
Production of biopharmaceuticals & biotherapeutics captured the largest share owing to the commercial success of biologics & biosimilars for clinical use in the current scenario. Pharmacists are leveraging the wide spectrum application of bioprocess engineering to develop organism derived therapeutics, which in turn are expected to drive the growth of this segment.
Moreover, companies are involved in enhancing their manufacturing capacity for biopharmaceutical development, which in turn is expected to provide avenues of lucrative growth. Other applications of this market include microbial biomass, microbial enzymes, microbial metabolites, biofuels, bioremediation, and biorefineries.
Depending upon the volume of culture to be produced, bioprocessing carried out can be segmented into two broad categories viz; small and industrial scale. Small-scale bioreactor systems provide parallel processing and allow the evaluation of a series of experiments for bioprocess optimization by being part of upstream processing. This factor is expected to be supportive of the projected growth of small-scale bioprocessing.
Bioprocessing for pharmaceutical development at the industrial scale has held the largest share in 2016. Continuous introduction of techniques and tools to support industrial-scale bioprocessing in the market has accelerated industrial-scale bioprocessing applications.
For instance, In June 2016, GE Healthcare introduced Capto Q XP chromatography resin. These chromatography resins are strong anion exchanger used to perform purification of large-scale biomolecules on the industrial scale. Such initiatives are anticipated to positively influence the growth of this segment over the forecast period.
Concerning use type, this market offers the multiple-use type and single-use type products. Single-use product-based bioprocessing is expected to witness the fastest growth during the forecast period. It is observed that substantial demand for innovation in single-use instruments, is anticipated to drive growth in this segment soon.
The number of advantages associated with single-use products is expected to boost the adoption in this segment. The major advantage associated with single-use type includes a reduction in the additional expenses associated with assembly, cleaning, process validation, operation, and equipment qualification of multiple-use bioprocess equipment.
Multiple-use products for bioprocessing dominated the 2016 market in terms of revenue generation. Low environmental impact associated with the implementation of multiple-use instruments and one-time investment is the major factor attributed to its large share in the current market.
The presence of well-established international players in the market, which are capable of performing in-house biopharmaceutical production has led to the large share of in-house biomanufacturing in 2016.
The complexity of biologics is one of the major factors for keeping the manufacturing process in-house. Furthermore, companies are using their in-house capabilities as a strategy to maintain the secrecy of their product development processes.
However, in the future market, the outsourced model of manufacturing is expected to grow lucratively. This is due to the substantial growth in the budgets for the outsourcing of biomanufacturing.
Besides, factors such as lack of sufficient expertise, limited capacity to perform industrial-scale bioprocess applications, and cost-saving advantages associated with contract services are expected to provide potential opportunities in the outsourcing sector.
As represented in the above figure, North America is the largest regional market accounting for 27.34% of the overall market revenue share in 2016. The dominance of this region concerning revenue generation is due to focused cutting-edge R&D in biomanufacturing in the region.
Other key factors that are involved in influencing the progress of the market in this region are developed infrastructure and rising funds for bioprocessing technology. Moreover, the presence of a substantial number of biomanufacturing facilities in this region has also attributed to the large share of this segment.
However, Asia Pacific is anticipated to be the most attractive regional market space in the coming years. Several companies are outsourcing biologics manufacturing as well as clinical trials in the region which is the key factor to drive progress in this region.
Some prominent players operating in the market include Merck KGaA (Sigma-Aldrich Co. LLC), Thermo Fisher Scientific, Inc.; Corning, Inc.; Sartorius AG; CESCO BIOENGINEERING Co., Ltd.; Bio-Process Group; Bioprocess Control AB; Eppendorf AG; Applikon Biotechnology; Lonza; PBS Biotech, Inc; Finesse; Binex Co., Ltd.; Meissner Filtration Products, Inc.; CMC Biologics; CellGenix GmbH; Boehringer-Ingelheim; Patheon; Samsung Biologics; Rentschler Biotechnologie GmbH; TOYOBO Co., Ltd, and Inno Biologics Sdn Bhd.
These participants are undertaking strategic initiatives to retain their significant share as well as to enhance industrial share. Strategic initiatives undertaken by the companies include product line enhancement, regional expansion, distribution network reinforcement, collaborations, and merger & acquisition.
For instance, in November 2016, Finesse Solutions, Inc launched a single-use 3-liter bioreactor vessel SmartVessel to serve biofuels and fermentation applications. This initiative is expected to enhance the company’s status in the coming years.
The base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Billion and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, France, China, India, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global large & small-scale bioprocessing (biopharmaceutical manufacturing) market based on workflow, product, application, scale, use-type, mode, and region:
Scale Outlook (Revenue, USD Billion, 2014 - 2025)
Industrial Scale (Over 50,000 Litre)
Small scale (Less than 50,000 Litre)
Workflow Outlook (Revenue, USD Billion, 2014 - 2025)
Product Outlook (Revenue, USD Billion, 2014 - 2025)
Cell Culture Products
Bags & Containers
Application Outlook (Revenue, USD Billion, 2014 - 2025)
Specialty Industrial Chemicals
Use-type Outlook (Revenue, USD Billion, 2014 - 2025)
Mode Outlook (Revenue, USD Billion, 2014 - 2025)
Regional Outlook (Revenue, USD Billion, 2014 - 2025)
Middle East & Africa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.